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 Introduction 
 The uncertainties inherent in the current staging mo-
dalities available for prostate cancer result in significant 
staging errors regarding clinically locally advanced tu-
mors – the clinical stage T3N0M0. The definition of this 
stage implies that clinically the cancer has seemed to have 
progressed locally beyond the prostatic capsule without 
having metastasized. The diagnostic methods used for 
staging are digital rectal examination plus transrectal ul-
trasound. While CT scanning is of little use in locally 
staging prostate cancer, the emerging possible role of 
MRI imaging still has to find a defined place in the stag-
ing of cT3 prostate cancer. 
 The insufficient accuracy of clinical staging in cT3 
cases and the inability of imaging studies to reliably di-
agnose pelvic lymph-node metastases (except in cases of 
very large lymph nodes) result in a significant staging er-
ror. Surgical series of cT3 cases reveal that this clinical 
group consists of T2 as well as T4 cases plus a substantial 
number of node-positive cases. A reliable separation of 
these subgroups of patients with cT3 disease is clinically 
not possible but can only be achieved in surgical series. 
 The result is that, until better and more reliable diag-
nostic methods have been found and validated, this un-
certainty in the management of cT3 prostate cancer dis-
ease will remain. While undoubtedly overstaged patients 
with actual T2 disease benefit from the application of po-
tentially curative treatment, those with occult systemic 
disease cannot at present be cured. 
 Abstract 
 The treatment of clinically locally advanced prostate car-
cinoma (stage cT3) remains controversial. One of the main 
reasons for this controversy results from the substantial stag-
ing error attached to the clinical diagnosis cT3 with over-
staged T2 tumors and understaged node-positive cases. 
Treatment options in this situation include radical prostatec-
tomy, external beam radiotherapy, immediate or delayed 
androgen deprivation treatment and the so-called ‘watchful 
waiting’. Acceptable and often surprisingly good tumor-spe-
cific survival rates have been reported for radical prostatec-
tomy in pT3 series – based on good clinical case selection – 
approaching those of pT2 series. In lymph node-positive pT3 
cases, adjuvant hormone deprivation seems to prolong sur-
vival which it does not in lymph node-negative pT3 disease. 
A benefit of adjuvant external beam radiotherapy after rad-
ical prostatectomy for pT3 cases in prolonging overall sur-
vival has not been shown, despite the fact that it can prevent 
or delay biochemical and local recurrence. External beam 
radiotherapy as the only treatment for cT3 disease results in 
unfavorable tumor-specific survival rates, which can be sig-
nificantly improved with adjuvant hormonal treatment with 
LHRH agonists. If, in case of advanced age and/or significant 
comorbidity, primary hormonal treatment is chosen, early 
hormonal deprivation therapy seems to offer marginal ben-
efits in survival compared to delayed treatment. 
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fore remains controversial. It should be remembered that 
the anatomic prostatic capsule is only a very thin mem-
brane, and that often in pT3 disease extension is via the 
perineural route. Thus, true locally advanced disease 
(cT3 without metastatic spread) in prostate cancer may 
not in itself represent a definite and huge negative leap in 
prognosis. 
 In current clinical practice, local radiotherapy with 
adjuvant hormone deprivation is often the preferred 
treatment for cT3 disease. In the USA, only 6% of patients 
with cT3 disease undergo radical prostatectomy, and 
even in younger patients this proportion amounts to only 
19%  [1] . 
 The use of validated nomograms such as the Partin 
tables  [2] can help to estimate the risk of locally advanced 
disease or lymph node metastases based on known pre-
dictors of these risks (such as PSA values, clinical stage, 
biopsy Gleason score). However, these estimations give 
only likelihoods but not certainty, and can therefore not 
reliably foretell an individual patient’s prognosis. Thus, 
for the time being, many uncertainties remain which 
make definite management decisions in cT3 cases often 
difficult. Randomized trials comparing different treat-
ment modalities in locally advanced prostate cancer are 
lacking  [3] . This review aims at evaluating what is cur-
rently known about the different management options 
for cT3 prostate cancer. 
 Staging of cT3 Disease 
 Digital rectal examination remains the basis of clini-
cal staging but is inherently uncertain. Surgical series of 
cT3 cases have shown that 9–27% represent clinically 
overstaged pT2 disease  [4–7] . Transrectal ultrasound, 
MRI or other imaging modalities cannot at present sub-
stantially improve on the results of digital rectal exami-
nation in the local staging of prostate cancer  [8–10] . 
 However, patients with suspected locally advanced 
disease who are considered to be candidates for poten-
tially curative treatment require a complete staging. 
Whether the rule that with a PSA level  ! 10 ng/ml osseous 
metastatic spread is unlikely, and therefore a bone scan is 
not indicated, also applies to locally advanced disease has 
not been shown. In unselected cases the rate of positive 
findings on bone scan in prostate cancer patients with a 
PSA  ! 10 ng/ml is 4%  [11] . 
 Surgical series of cT3 cases have also shown node-pos-
itive rates of 27–48%  [5–7, 12, 13] . The only exception, 
with a markedly lower rate of pN+ cases, is the series re-
ported by van Poppel et al.  [14] with only 11%, perhaps 
due to a highly selected cohort. The risk of nodal spread 
in cT3 disease is, as in T2 disease, correlated with Glea-
son score, PSA value and possible seminal vesicle inva-
sion. Thus the risk of nodal spread in cT3 disease with 
Gleason 8–10 cancer and PSA values between 4 and
10 ng/ml is already present in 32%  [12] . Staging for met-
astatic disease as well as surgical lymph node staging 
thus seem absolute requirements in patients with cT3 
disease before undertaking a potentially curative local 
treatment. 
 Prognosis of Locally Advanced Prostate Cancer 
 The effect of potentially curative treatment modalities 
on the course of truly locally advanced prostate cancer is 
difficult to assess, due to a lack of conclusive randomized 
studies and the inconsistently selected patients in treat-
ment studies, which mostly are retrospective. In the pre-
PSA era, tumor-specific survival rates in cT3 disease after 
radiotherapy or conservative treatment of 50% and of 
80% after radical prostatectomy were observed  [15] . A 
biochemical recurrence after radical prostatectomy in 
pT3 disease can be expected in 40% within 10 years  [16] . 
However, variability is great depending on the risk fac-
tors, biopsy Gleason score, preoperative PSA and seminal 
vesicle status  [17, 18] . This variability ranges between a 
10-year recurrence rate of over 90% in poor-risk groups 
to one of under 10% in low-risk groups. Thus, manage-
ment decisions in cT3 disease must – as in clinically local-
ized prostate cancer – not only take general prognostic 
factors for overall survival into account (age, comorbid-
ity and quality of life) but also these tumor-specific 
known risk factors (tumor differentiation by biopsy Glea-
son score and PSA). 
 Radical Prostatectomy in cT3 Disease 
 Radical prostatectomy in cT3 disease results in incom-
plete tumor removal (R1) in 22–60% of cases  [6, 14, 19] , 
and up to 48% of patients will have lymph node disease. 
Thus, it can be argued that for these patients surgery does 
not achieve a great deal while potentially incurring sig-
nificant morbidity. However, it may be questioned wheth-
er this today – in the PSA era and after significant devel-
opment in the surgical technique of radical prostatecto-
my – stills holds true. 
 Treatment of Locally Advanced Prostate 
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Mayo Clinic have for a long time advocated the use of 
radical prostatectomy in locally advanced prostate can-
cer, and have recently published the largest single-center 
surgical series on radical prostatectomy in cT3 disease 
with a follow-up of 15 years  [6] . They operated on a total 
of 841 patients with cT3 disease out of over 8,000 radical 
prostatectomies altogether between 1987 and 1997. For 
the cT3 patients the mean age was 66 years, mean preop-
erative PSA 10.2 ng/ml, median biopsy Gleason score 7, 
and 23% had received neoadjuvant hormonal treatment. 
Overstaging was substantial with 27% of cT3 cases having 
pathological stage pT2 disease while positive lymph nodes 
were also seen in 27%. PSA recurrence-free and disease-
specific survivals as well as overall survival in the cT3 
group were significantly lower than in the cT2 group, but 
the actual differences were small. Morbidity due to com-
plications of radical prostatectomy in the cT3 group was 
not different from that in the cT2 group. In the cT3 group, 
full continence after 1 year was reported to be 79%, while 
grade 3 stress urinary incontinence was seen in 6.5%; 
75% had complete loss of potency, with 74% having un-
dergone radical prostatectomy without nerve-sparing. 
 In a retrospective multicenter analysis of 345 radically 
operated cT3 patients, 41% node-positive cases were seen 
and the actuarial 10-year disease-specific survival was 
only 57%. In this series disease-specific survival was 
clearly dependent on tumor grade and amounted to only 
29% in poorly differentiated tumors  [5] . Amling et al.  [7] , 
however, reported an 84% disease-specific 10-year sur-
vival rate in cT3 patients. The group from Rotterdam in 
their single-center series of surgically treated cT3 patients 
reported an overall survival of 60% and a disease-spe-
cific survival of 72% after 10 years. The latter was again 
dependent on tumor grade  [22] . Van Poppel et al.  [14] 
observed a 5-year biochemical recurrence-free rate of 
60% in pT3a patients with a preoperative PSA  ! 10 ng/ml. 
In a recent series of radical prostatectomy as monothera-
py in cT3 patients with a mean follow-up of just over 5 
years, Isorna Martinez de la Riva et al.  [4] reported a dis-
ease-specific survival of 100% and a likewise grade-de-
pendant biochemical progression rate of 36%. 
 Beyond survival data, another consideration seems of 
importance. In addition to offering potential cure, radi-
cal removal of the prostate can improve local control and 
reduce local complications. This in itself may improve 
quality of life despite eventually progressive disease. The 
group of Walsh et al.  [23] reported a case-control study 
of pelvic lymphadenectomy alone versus pelvic lymphad-
enectomy with radical prostatectomy in stage D1 patients. 
In this study they found a non-significant trend towards 
improved survival in the prostatectomized group after 10 
years. The group of Frohmüller et al.  [24] showed already 
in 1995 in lymph node-positive patients (T1-3pN1-2M0), 
in a comparative study between pelvic lymphadenectomy 
followed by hormonal deprivation versus pelvic lymph-
adenectomy plus radical prostatectomy followed by hor-
monal therapy, a significant benefit in disease-specific 
survival as well as local progression and complication 
rate after 10 years for the prostatectomized group (10-
year disease-specific survival 32 vs. 71%, local progres-
sion rate 8 vs. 69%)  [24] . These studies demonstrate that 
radical surgery in pT3 patients may in the long run im-
prove quality of life by reducing local progression and 
complications, despite the fact that cure cannot be 
achieved. 
 Thus, patients with cT3 prostate cancer who may be 
candidates for radical prostatectomy should have favor-
able risk factors. In addition to a sufficient general life 
expectancy and low comorbidity, the biopsy Gleason 
score should be 7 or less, the PSA should not exceed
20 ng/ml and seminal vesicle invasion should clinically 
be unlikely. Nerve-sparing surgery in this patient group, 
however, is not an option. A high rate of positive margins 
is to be expected (up to 60%). This can possibly be re-
duced with neoadjuvant hormonal treatment which, 
however, does not influence the biochemical recurrence 
rate  [25] . 
 Positive Lymph Nodes 
 In case of positive lymph nodes (pN+) in stage cT3 
prostate cancer, the disease is systemic and carries a re-
duced prognosis. In surgical series of cT3 cases the node-
positive rate is between 27 and 41%  [5–7] . The published 
retrospective series of node-positive pT3 disease have 
shown that disease-specific survival is prolonged by ad-
juvant hormone deprivation. Five- and 10-year progres-
sion-free survival rates of 41–83 and 25–71%, respective-
ly, have been reported  [23, 24, 26–29] . The ECOG as well 
as the EORTC studies have shown a significant progres-
sion-free survival benefit for an early versus a deferred 
hormone-deprivation therapy  [22, 30] . 
 The finding of positive lymph nodes during surgery in 
cT3 patients raises the question of whether to perform 
radical prostatectomy or not. The published studies on 
this question have yielded a definite answer to this ques-
tion. Zwergel et al. reported a relatively good disease-spe-
cific 10-year survival of 74% after radical prostatectomy 
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in pN+ disease. The risk of progression in this series was 
proportional to the extent of lymph node metastases. 
With minimal lymph node spread the risk of disease-spe-
cific mortality after radical prostatectomy is only mar-
ginally elevated compared to pN0 cases with a hazard 
ratio of 1.5 in patients with one positive lymph node. In 
this patient group, disease-specific 10-year survival rates 
of 94% have been reported  [31] . The group from Berne, 
which stresses the necessity of extensive pelvic lymphad-
enectomy, has shown this relationship between prognosis 
and the extent of micrometastatic lymph node spread 
with, however, less favorable disease-specific survival 
rates  [32] . 
 Adjuvant Treatment after Radical Prostatectomy for 
pT3 Disease 
 Until recently there was no rationale for adjuvant ra-
diotherapy in lymph node-negative pT3 disease, since the 
majority of locally advanced prostate carcinomas tend to 
progress systemically rather than locally after radical 
prostatectomy. However, there are indications that adju-
vant radiotherapy (60 Gy over 6 weeks) can probably re-
duce the rate of biochemical progression and local recur-
rences  [33–35] . Recently, Bolla et al.  [36] published the 
results of a large randomized trial of adjuvant immediate 
postoperative radiotherapy in pN0M0 patients with pT3 
disease and/or positive margins, and found a significant-
ly increased biochemical progression-free survival and 
an increased clinical progression-free survival within a 
follow-up period of 5 years. However, it has so far not 
been possible to show a benefit in disease-specific sur-
vival  [37] . Also, there is no definitely proven need for ad-
juvant hormonal treatment in lymph node-negative pT3 
prostate cancer. While the EPC study has shown a sig-
nificant reduction of the progression rate in prostatecto-
mized locally advanced prostate cancers with adjuvant 
antiandrogenic treatment, this did not result in a prolon-
gation of the disease-specific survival. 
 While there is thus no proof from randomized studies 
for a general benefit of adjuvant hormone deprivation 
treatment after radical prostatectomy, advantages from 
adjuvant hormone treatment may be seen for specific 
subgroups of patients ( table 1 ). In a retrospective study a 
survival advantage was seen in patients with seminal ves-
icle invasion  [38] and in patients with diploid tumors and 
lymph node-positive disease  [39, 40] . A small random-
ized study with 98 patients only and a median follow-up 
of 7 years showed a superiority of early versus deferred 
treatment concerning disease-specific and overall sur-
vival in patients with minimal lymph node disease after 
radical prostatectomy  [41] . The results of this study have 
so far, however, not been confirmed by other trials  [42] . 
An EORTC study with 302 lymph node-positive patients 
who did not undergo radical prostatectomy showed no 
advantage for early hormonal treatment, despite a three-
fold larger study group than the control group  [43] . In a 
randomized prospective controlled multicenter study in 
Germany and Austria, 352 node-negative patients with 
locally advanced prostate cancer were treated with either 
flutamide 750 mg daily or by watchful waiting until clin-
ical progression occurred. After a median follow-up of 6 
years, no survival advantage was seen for the adjuvant 
hormonal treatment  [44] . 
 Neoadjuvant Treatment 
 A definite benefit of neoadjuvant hormonal treatment 
before radical prostatectomy has never been proven, de-
spite numerous randomized studies undertaken  [45–49] . 
Neoadjuvant treatment specifically for locally advanced 
prostate cancer, however, has only been examined in a 
limited number of studies with a small number of pa-
tients. Neoadjuvant treatment can reduce the tumor vol-
Table 1. Prospective randomized studies on adjuvant hormonal treatment after radical prostatectomy
Group (first author) Stages Treatment Progression Survival
Messing, 1999 [41], 2003 [30] pN+ Orchidectomy or 
LHRH analogues
Advantage for adjuvant treatment Advantage for
adjuvant treatment
Prayer-Galetti, 2000 [56] Stage C LHRH analogues Advantage for adjuvant treatment No data available
Wirth, 2004 [44] pT3-4pN0 Flutamide Advantage for adjuvant treatment No difference
Wirth, 2001 [57], 2004 [58];
McLeod, 2006 [59]
pT1b-4, N0-1M0 Bicalutamide Advantage for adjuvant treatment No difference
 Treatment of Locally Advanced Prostate 
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This, however, does not influence survival or progression 
parameters. In one randomized study, a trend towards a 
reduced clinical progression rate was seen in patients who 
received neoadjuvant as well as adjuvant hormonal treat-
ment compared to the control group, which received only 
adjuvant hormonal treatment  [53] . In this study, however, 
follow-up was limited to only 2 years. 
 There are still only very few data concerning potential 
advantages which might be achieved with neoadjuvant 
chemotherapy in high-risk patients before radical prosta-
tectomy with docetaxel. Toxicity is mild. Histopatholog-
ically complete remissions are not to be expected  [54, 55] 
and the use of chemotherapy in this setting should cur-
rently only be performed in controlled clinical trials. 
 Conclusions 
 In well-selected patients with clinically locally ad-
vanced prostate cancer who have a favorable risk factor 
profile regarding preoperative PSA and biopsy Gleason 
score and who have limited comorbidity and sufficient 
life expectancy, curative treatment is advisable. Radical 
prostatectomy in these patients should be a preferred op-
tion, also considering the large staging error which oc-
curs in this setting. Pelvic lymphadenectomy in cT3 dis-
ease is indispensable, due to a high number of node-pos-
itive cases which must be expected. Recent series, 
however, have demonstrated that in node-negative pT3 
prostate cancer, radical prostatectomy achieves biochem-
ical progression and disease-specific survival rates in pa-
tients with well to moderately differentiated disease 
which are only marginally worse than in those with pT2 
disease. In addition, there are data demonstrating a re-
duction in local complication rate in patients with cT3 
prostate cancer after radical prostatectomy, which im-
proves quality of life and reduces hospital time during the 
remaining life span of incurable patients with progressive 
disease. Adjuvant hormonal treatment is of proven ben-
efit only in node-positive surgically treated patients. Ad-
juvant radiotherapy after radical prostatectomy in 
pT3pN0M0 patients improves biochemical and clinical 
progression-free survival. 
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